LA Private

October 2023

Stocks of the Hour: Noxopharm, Redstone Resources, Lake Resources

Noxopharm (ASX:NOX) announces that the US FDA has granted Orphan Drug Designation (ODD) status to Noxopharm’s CRO-67 preclinical drug candidate, for the treatment of pancreatic cancer. Noxopharm CEO Dr Gisela Mautner said, “our pancreatic cancer program is a high priority, and we are committed to progressing its development as quickly as possible. Further studies are

Stocks of the Hour: Noxopharm, Redstone Resources, Lake Resources Read More »

RBA’s Michelle Bullock steers steady course amidst economic uncertainty

Steady as Michelle Bullock took the reins as the new Governor at the Reserve Bank, judging by the statement from her first central bank monetary policy meeting on Tuesday. The RBA left the cash rate unchanged at 4.1% for the fourth consecutive month but also maintained the hawkish approach of her predecessor, warning that a

RBA’s Michelle Bullock steers steady course amidst economic uncertainty Read More »